New Products	9 Months Ended
Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NEW PRODUCTS	NEW PRODUCTS Totect ^® In late July 2017, the Company initiated distribution and sale of Totect (dexrazoxane hydrochloride) in the United States. This followed the FDA approval of the updated labeling and product manufacturer for the product. In late September 2017, the Company announced the launch of Totect promotion in the United States. Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy. It treats anthracycline extravasation that occurs when the injected medication escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries or procedures and enables patients to continue their essential anti-cancer treatment. In preparation for the Totect promotional launch, the Company completed the training of its sales and medical organization, stocked the product at select wholesalers serving hospitals, and recently introduced the product website. Totect is supported by Cumberland's hospital sales force. The Company launched Totect during a national shortage of dexrazoxane. It's our second oncology support product and the second product licensed to it through the Strategic Alliance with Clinigen Group plc ("Clinigen"). The Company began generating revenue from the sale of Totect during the third quarter of 2017. Totect contributed $2.6 million in net revenue for the three months ended September 30, 2017. Cardioxane^® During August 2017, the Company also began shipments of Cardioxane (dexrazoxane hydrochloride, injection) which is used to support oncology patients from the cardiac complications associated with certain chemotherapeutic agents. These shipments were under a special, expedited clearance from the FDA to address the shortage of dexrazoxane in the United States. The Company intends to make Cardioxane available in the United States through the end of 2017, until the current dexrazoxane drug shortage is alleviated. The Company is distributing Cardioxane through its Strategic Alliance with Clinigen who is supplying the product and has been selling it in several markets outside the United States. The Company began generating revenue from the sale of Cardioxane during the third quarter of 2017. Cardioxane contributed $0.3 million in net revenue for the three months ended September 30, 2017.

NEW PRODUCTS

Totect ^®

In late July 2017, the Company initiated distribution and sale of Totect (dexrazoxane hydrochloride) in the United States. This followed the FDA approval of the updated labeling and product manufacturer for the product. In late September 2017, the Company announced the launch of Totect promotion in the United States.

Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy. It treats anthracycline extravasation that occurs when the injected medication escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries or procedures and enables patients to continue their essential anti-cancer treatment.

In preparation for the Totect promotional launch, the Company completed the training of its sales and medical organization, stocked the product at select wholesalers serving hospitals, and recently introduced the product website. Totect is supported by Cumberland's hospital sales force.

The Company launched Totect during a national shortage of dexrazoxane. It's our second oncology support product and the second product licensed to it through the Strategic Alliance with Clinigen Group plc ("Clinigen").

The Company began generating revenue from the sale of Totect during the third quarter of 2017. Totect contributed $2.6 million in net revenue for the three months ended September 30, 2017.

Cardioxane^®

During August 2017, the Company also began shipments of Cardioxane (dexrazoxane hydrochloride, injection) which is used to support oncology patients from the cardiac complications associated with certain chemotherapeutic agents. These shipments were under a special, expedited clearance from the FDA to address the shortage of dexrazoxane in the United States. The Company intends to make Cardioxane available in the United States through the end of 2017, until the current dexrazoxane drug shortage is alleviated.

The Company is distributing Cardioxane through its Strategic Alliance with Clinigen who is supplying the product and has been selling it in several markets outside the United States.

The Company began generating revenue from the sale of Cardioxane during the third quarter of 2017. Cardioxane contributed $0.3 million in net revenue for the three months ended September 30, 2017.